Saturday, July 11, 2026

Drug profile · INN

golimumab-sldi

golimumab-sldi (IMMGOLIS) is an FDA-listed pharmaceutical active ingredient. Route of administration: solution. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 1
Drug details — golimumab-sldi
US status
approved
Class
Route
SOLUTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

golimumab-sldi (IMMGOLIS) is an FDA-listed pharmaceutical active ingredient. Route of administration: solution. Current US regulatory status: approved.

Key facts

INN golimumab-sldi
Brand IMMGOLIS
Route SOLUTION
Formulation INJECTION

Approval history

Authority Status Date
FDA approved

Recent coverage

Frequently asked questions

What is golimumab-sldi?

golimumab-sldi (IMMGOLIS) is an FDA-listed pharmaceutical active ingredient. Route of administration: solution. Current US regulatory status: approved.

What is the brand name for golimumab-sldi?

IMMGOLIS is a marketed brand name for golimumab-sldi. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of golimumab-sldi?

golimumab-sldi has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.